Cisplatin is a widely used chemotherapeutic drug in the treatment of several solid tumors. However, the resistance developed to the drug together with its severe side effects, such as nephrotoxicity, have been obstacles to a more efficient treatment. Cisplatin is also used in the treatment of leishmaniose. In this study, a methodology was developed to synthesize cisplatin with ligands derived from aminopurines, with the aim of obtaining products with antineoplasic potential and biological activity, but presenting a reduction of its toxicity. The synthesis of the ligand consists of two stages, the first involves the oxidation of the 6-methylmercaptopurine to 6-methylsulphonilpurine and is followed by the aminolysis of the latter to respective 6-aminopurines. In this second stage a study was made of the nucleofilic character of these aromatic amines. In the complex formation stage, that is, in the interaction between the 6-aminopurines and cisplatin, parameters such as temperature, time of reaction, pH and solvent solubility were analyzed. The relationship between the group in the position 6 of these 6-aminopurines and their reactivity with cisplatin was also studied. The choice of 6-aminopurines as ligants was fundamental, the literature1.7 shows a huge biological activity of these composts and the leishmania protozoary needs the purine media to survine. All synthesized substances were characterized using the following techniques: CHN, TGA, IR, NMR-1H, NMR-13C and Mass Spectrometry (LDI). Biological activity testes showed that one of the compounds has leishmanicide